IIT Guwahati develops mechanism to treat 1,000 litre contaminated water for Rs 20
community scale water treatment
system that removes fluoride and iron from groundwater and can treat up to 20,000 litre of contaminated water per day, officials said.
The findings of the research have been published in the prestigious ACS ES&T Water journal.
The researchers claimed the system was highly affordable and could treat 1,000 litre of water at a paltry Rs 20.
According to Mihir Kumar Purkait, Professor at Department of Chemical Engineering,
IIT Guwahati
, fluoride, a mineral generally used in dental care products, pesticides, fertilisers and some industrial processes, can enter groundwater either naturally or through human activities such as agriculture and manufacturing.
"Consumption of water with excess fluoride presence can lead to skeletal-fluorosis, a serious health condition in which bones harden and joints become stiff, making physical movement difficult and painful. In India, states including Rajasthan, Telangana, Andhra Pradesh, Karnataka, Haryana, and Gujarat, among others, face high levels of fluoride in groundwater," Purkait said.
The IIT Guwahati research team developed a four-step system that ensures a cost-effective and energy-efficient technology for contaminated water treatment.
Purkait said the hydrogen and oxygen bubbles produced during electrolysis interact with air bubbles, assisting in lifting pollutant particles to the surface.
The selection of electrode material depends on factors like low cost, low oxidation potential and high electro-positivity after dissolution.
"Among available options, aluminum has proven highly effective, particularly in the removal of iron, arsenic, and fluoride under optimal operational conditions," he said.
The research team tested the developed system under real-world conditions for 12 weeks and recorded consistent performance.
The results have shown removal of 94 per cent iron and 89 per cent fluoride from the wastewater, bringing the levels within safe limits set by Indian standards.
"A key feature of the developed system is its cost effectiveness, with Rs 20 per 1,000 liters of treated water, making it highly affordable. The developed technology requires minimal supervision and has a projected lifespan of 15 years with electrode replacement scheduled every six months," he said.
The study proposes a method to estimate electrode life using a built-in safety factor to ensure timely maintenance.
As a pilot project, in support with the Public Health Engineering Department of Assam, the developed technology has been successfully installed by Kakati Engineering Pvt Ltd in Changsari, Assam.
"We are also exploring the use of solar or wind power to operate the unit and to utilise the hydrogen gas generated during
electrocoagulation process
. By integrating smart technologies such as real-time sensors and automated controls, we will be able to further reduce the need for manual intervention, making the system more effective for remote and underserved areas," he said.
The research team also aims to combine the current system with other water treatment methods to enhance performance and provide a decentralised water treatment solution. PTI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
44 minutes ago
- Indian Express
Govt defends revised framework for SO2 emission norms
The Union Environment Ministry Monday defended its July 11 order which introduced a revised framework for thermal power plants to meet sulphur dioxide (SO2) emission norms and said that contrary to 'claims of regulatory dilution', the decision was based on evidence, sectoral emission trends and sustainability imperatives. The ministry's revised compliance framework exempted a large number of coal- and lignite-based plants from the mandate of retro-fitting plants with flue gas desulphurization devices. The ministry said that there was no notable difference in ambient SO2 concentrations between cities where plants had fitted the technology versus those that had not. SO2 is a harmful gas and is emitted when coal is burned in energy production. It also aids formation of secondary pollutants. 'The norms of Sulphur Dioxide emissions from Thermal Power Plants notified on 11th July is based on extensive consultations with stakeholders and research institutions regarding the effectiveness and rationale behind stack emission standards for SO2 on 537 TPPs throughout the country, and its role in overall ambient air pollution of the region,' a ministry statement said. 'Further, the norms were based on detailed scientific studies which were carried out by premier institutions such as IIT Delhi, National Institute of Advanced Studies as well as by the National Environmental Engineering Research Institute (NEERI)…besides scientific examination by the Central Pollution Control Board,' it added. The ministry said: 'Current exposure levels provide no credible evidence to suggest that SO2, under prevailing ambient conditions, is a major public health concern. Moreover, sulfate (sic) aerosols formed from SO2 constitute a relatively small fraction of PM (particulate matter) 2.5.' The SO2 emission norms for coal and lignite power plants were first introduced in 2015. Later, the compliance timelines for plants were divided into three categories, based on the location of the plants. The July 11 order said that plants in Category A, which are located within 10 kms of the Delhi-National Capital Region (NCR) or cities with a million plus population have to continue complying with the norms by the end of 2027. For category B plants, located within 10-km of critically polluted areas or cities not in compliance with national ambient air quality standards will apply on a case to case basis, based on recommendations of an expert appraisal committee. For Category C plants, located outside of these two areas, will be completely exempted from meeting the SO2 norms. However, they will have to comply with stack height criteria. The ministry notification said that thermal power plants due to retire before December 2030 shall not be required to meet the SO2 emission norms, provided they submit an undertaking for exemption. A compensation at the rate of Rs 0.40 per unit of electricity generated would be levied if they continue to operate beyond the 2030 timeline. Out of the 600 units of coal fired power plants, 537 were identified for installation of flue-gas desulphurization (FGD) technology, to curb SO2 emissions. The ministry said in a detailed note as per rough estimates, Rs 2.54 lakh crore of capital expenditure would be needed for nationwide retrofitting of coal-based capacity with FGD devices to meet SO2 emission norms. ' In light of the limited incremental benefit to ambient PM2.5 levels and the high marginal cost of pollution reduction, such investments must be carefully scrutinized,' the ministry said. 'The revised sulphur dioxide emission policy is not a rollback of environmental safeguards, but a pragmatic, scientifically justified shift toward more targeted, cost-effective, and climate-coherent regulation. It reflects declining ambient sulphur dioxide levels, recognizes the limited role of sulphur dioxide in driving PM2.5 health impacts, and weighs the disproportionate resource and environmental costs of indiscriminate FGD mandates,' the ministry added.
Time of India
an hour ago
- Time of India
India witnessed startup boom in last 10 years; students must focus on entrepreneurship: Jitendra Singh
He said the creation of the Rs 1 lakh crore National Research Foundation (NRF-Anusandhan) marks a significant push to encourage private sector investment in research and development, thereby strengthening the country's research ecosystem. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Union Minister Jitendra Singh on Monday highlighted the startup boom in the country, noting that the number of startups has grown from 350 to nearly 1.75 lakh in the last decade and urged the student fraternity to shift their focus from being job seekers to becoming job creators He said the creation of the Rs 1 lakh crore National Research Foundation (NRF-Anusandhan) marks a significant push to encourage private sector investment in research and development, thereby strengthening the country's research ecosystem."From just 350 startups a decade ago, India now has over 1.75 lakh startups - creating 17.56 lakh jobs, more than many government recruitment initiatives," Singh said while addressing events, first at IIM and then at IIT in Jammu."We urge students to shift their mindset from being job seekers to becoming job creators, leveraging the enormous support available through various startup schemes," he Minister said that this transformative initiative is further bolstered by recent reforms that empower vice-chancellors to approve global tenders up to Rs 200 crore, simplifying and expediting the procurement of advanced research equipment and emphasised that such measures will accelerate scientific progress and help position India as a global leader in research and innovation."Over 1,600 obsolete rules have been scrapped to streamline governance and reduce bureaucratic hurdles. The General Financial Rules (GFRs) have been relaxed, enabling faster procurement and greater flexibility for researchers," he that 56 per cent of India's patent filings now come from Indian residents, he said that India's rank in the Global Innovation Index has improved to 39 from 81."India now ranks fourth globally in scientific publication output, highlighting the increasing academic and research contributions from Indian institutions," Singh said."Our space missions like Chandrayaan and Gaganyaan have made India a global science and technology leader," he added, citing the success of experiments aboard these missions, including Shubhanshu's, which are setting benchmarks in life sciences and Minister inaugurated a new hostel on the campus, comprising four blocks, together providing 688 single-occupancy rooms. He also noted that only last week, the Union Cabinet had authorised the director to approve tenders up to Rs 200 crore.
Mint
an hour ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
